Mona Mohammed Abdelrahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mona Mohammed Abdelrahman has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Amira Maher
Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University,Sohag, Egypt
2 shared publicationsNoha Saber Shafik
Sohag Univ, Fac Med, Med Microbiol & Immunol Dept, Sohag, Egypt
2 shared publicationsRamy Mamdouh Abd El Hamid
Tropical medicine and gastroentrology , sohag university hospital
2 shared publicationsSafaa Khalaf Abd Allah
Tropical medicine and gastroenrology, facultyof medicine, sohag university
2 shared publicationsAhmed N Nour Eldin
Internal Medicine Department, Faculty of Medicine, Sohag University, Sohag, Eygpt
1 shared publicationAhmed Nagah
Internal medicine department, Faculty of Medicine, Sohag University, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by SAGE Publications in Clinical Pathology
- Vol. 16
Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter pylori-Associated Chronic Gastritis
Background: Chronic gastritis (CG) is a very common disease. More than half of the worldwide population suffers from symptoms of CG. This disease has received great attention since the discovery of H. pylori as the most important cause of CG. Symptoms experienced by patients with CG are attributed to H. pylori-induced inflammatory reactions. Heparanase (HPSE) is a mammalian β-endoglucoronidase. In inflammation; HPSE degrades and remodels the extracellular matrix’s heparan sulfate polysaccharide chains liberating heparan sulfate-bound cytokines and chemokines, HPSE also facilitates movement of inflammatory cells. Aims: This study aimed to detect the function of HPSE in CG by correlating levels of HPSE expression with histopathological features of CG, including H. pylori infection, acute and chronic inflammatory cells, mucosal atrophic and/or metaplastic features. Methods: Ninety-five upper endoscopic-guided gastric punch biopsies were enrolled in this study. From each specimen, formalin-fixed and paraffin-embedded tissue blocks were prepared. Tissue sections were stained by Hematoxylin and eosin, Giemsa, and anti-heparanase antibody. Results: HPSE expression was statistically associated with H. pylori infection ( P-value < .000), and intensity of chronic lymphocytic inflammatory infiltrate in the gastric mucosal tissues ( P = .004). High levels of HPSE expression were also related to the presence of neutrophils in the gastric surface epithelium and lamina propria ( P-value < .009). Conclusions: HPSE expression was upregulated in H. pylori-associated chronic gastritis. Thus, future therapeutic agents that could specifically inhibit HPSE enzyme activity, may aid in the reduction of sequelae of H. pylori infection.
- 1 January 2023
- Published by SAGE Publications in Clinical Pathology
- Vol. 16
Open AccessEvaluation of Immunohistochemical Expression of Heparanase in Helicobacter pylori-Associated Chronic Gastritis
Background: Chronic gastritis (CG) is a very common disease. More than half of the worldwide population suffers from symptoms of CG. This disease has received great attention since the discovery of H. pylori as the most important cause of CG. Symptoms experienced by patients with CG are attributed to H. pylori-induced inflammatory reactions. Heparanase (HPSE) is a mammalian β-endoglucoronidase. In inflammation; HPSE degrades and remodels the extracellular matrix’s heparan sulfate polysaccharide chains liberating heparan sulfate-bound cytokines and chemokines, HPSE also facilitates movement of inflammatory cells. Aims: This study aimed to detect the function of HPSE in CG by correlating levels of HPSE expression with histopathological features of CG, including H. pylori infection, acute and chronic inflammatory cells, mucosal atrophic and/or metaplastic features. Methods: Ninety-five upper endoscopic-guided gastric punch biopsies were enrolled in this study. From each specimen, formalin-fixed and paraffin-embedded tissue blocks were prepared. Tissue sections were stained by Hematoxylin and eosin, Giemsa, and anti-heparanase antibody. Results: HPSE expression was statistically associated with H. pylori infection ( P-value < .000), and intensity of chronic lymphocytic inflammatory infiltrate in the gastric mucosal tissues ( P = .004). High levels of HPSE expression were also related to the presence of neutrophils in the gastric surface epithelium and lamina propria ( P-value < .009). Conclusions: HPSE expression was upregulated in H. pylori-associated chronic gastritis. Thus, future therapeutic agents that could specifically inhibit HPSE enzyme activity, may aid in the reduction of sequelae of H. pylori infection.
- Open Access
- 1 October 2022
- Published by Egyptian Knowledge Bank in african journal of gastroenterology and hepatology
- Vol. 5 (2) , 48-63
Assessment of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD); A Single Center Experience
Background:Non-alcoholic fatty liver disease (NAFLD) represents a considerable percentage of chronic liver diseases worldwide. The liver is not the only organ affected by NAFLD but also affects other organs such as the cardiovascular system and the kidney. In recent decades, there has been a growing body of evidence linking NAFLD to kidney function. So, the current study aims to assess the percentage of chronic kidney disease (CKD) in NAFLD patients and its link to different stages of hepatic fibrosis. Patients and Methods: A case-control study evaluated 62 non-alcoholic fatty liver disease patients and a control group of 38 volunteers with apparently healthy livers (normal echo pattern by ultrasound). All participants underwent serum creatinine measurement, albumin creatinine ratio in urine, calculation of estimated glomerular filtration rate (eGFR), abdominal ultrasound, and fibroScan examination.Results: The authors showed that the percentage of patients with chronic kidney diseases (patients with GFR less than 60 ml or micro-albuminuria) were significantly higher among NAFLD groups than in healthy controls. There was a significant positive correlation between the albumin creatinine ratio and subcutaneous fat thickness, BMI, and steatosis degrees. The estimated glomerular filtration rate (eGFR) and the age of the patients had a significant negative correlation. In comparison, the eGFR and AST levels had a significant positive correlation.Conclusions: Our results showed that NAFLD substantially raises the risk of getting CKD.
- 1 October 2022
- Published by Egyptian Knowledge Bank in african journal of gastroenterology and hepatology
- Vol. 5 (2) , 48-63
Open AccessAssessment of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD); A Single Center Experience
Background:Non-alcoholic fatty liver disease (NAFLD) represents a considerable percentage of chronic liver diseases worldwide. The liver is not the only organ affected by NAFLD but also affects other organs such as the cardiovascular system and the kidney. In recent decades, there has been a growing body of evidence linking NAFLD to kidney function. So, the current study aims to assess the percentage of chronic kidney disease (CKD) in NAFLD patients and its link to different stages of hepatic fibrosis. Patients and Methods: A case-control study evaluated 62 non-alcoholic fatty liver disease patients and a control group of 38 volunteers with apparently healthy livers (normal echo pattern by ultrasound). All participants underwent serum creatinine measurement, albumin creatinine ratio in urine, calculation of estimated glomerular filtration rate (eGFR), abdominal ultrasound, and fibroScan examination.Results: The authors showed that the percentage of patients with chronic kidney diseases (patients with GFR less than 60 ml or micro-albuminuria) were significantly higher among NAFLD groups than in healthy controls. There was a significant positive correlation between the albumin creatinine ratio and subcutaneous fat thickness, BMI, and steatosis degrees. The estimated glomerular filtration rate (eGFR) and the age of the patients had a significant negative correlation. In comparison, the eGFR and AST levels had a significant positive correlation.Conclusions: Our results showed that NAFLD substantially raises the risk of getting CKD.
- 21 June 2022
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
Assessment of Serum Vitamin D and Total Calcium Levels in COVID-19 Infected Patients and Their Relation to Disease Severity
Background and study aim: COVID-19 is a highly contagious viral infection that was initially discovered in late 2019 in China. Vitamin D was proposed as a COVID-19 severity indicator by many authors. However, the role of hypocalcemia has not yet been well established. So we evaluated serum levels of vitamin D and total calcium in adult patients infected with COVID-19 and correlated vitamin D and calcium levels with the severity and prognosis of the COVID-19 infection. Patients and Methods: Our study evaluated 98 patients (50 females, 48 males) who were diagnosed with positive SARS-CoV-2 polymerase chain reaction. The patients were categorized into severe and non-severe COVID-19 based on the Egyptian protocol for the management of COVID-19 patients. Serum vitamin D and calcium levels were estimated in all patients. Results: In severe COVID-19 individuals, serum vitamin D levels were significantly lower (P = 0.04). However, there was no statistically significant change in serum calcium levels between severe and non-severe COVID-19 patients (P = 0.7) despite the high prevalence of hypocalcemia in our cohort (88%, 86/98). There was no statistically significant difference in the blood levels of both vitamin D and calcium between the improved group of patients and the death group (P = 0.5, 0.1 respectively). Conclusion: Vitamin D deficiency is a risk factor for disease progression and severity in COVID-19 patients. Hypocalcemia is not linked to COVID-19 severity despite its high prevalence in these patients. However, to back up these findings, more research with bigger sample size is required .
- 21 June 2022
- Published by Egyptian Knowledge Bank in Afro-Egyptian Journal of Infectious and Endemic Diseases
Assessment of Serum Vitamin D and Total Calcium Levels in COVID-19 Infected Patients and Their Relation to Disease Severity
Background and study aim: COVID-19 is a highly contagious viral infection that was initially discovered in late 2019 in China. Vitamin D was proposed as a COVID-19 severity indicator by many authors. However, the role of hypocalcemia has not yet been well established. So we evaluated serum levels of vitamin D and total calcium in adult patients infected with COVID-19 and correlated vitamin D and calcium levels with the severity and prognosis of the COVID-19 infection. Patients and Methods: Our study evaluated 98 patients (50 females, 48 males) who were diagnosed with positive SARS-CoV-2 polymerase chain reaction. The patients were categorized into severe and non-severe COVID-19 based on the Egyptian protocol for the management of COVID-19 patients. Serum vitamin D and calcium levels were estimated in all patients. Results: In severe COVID-19 individuals, serum vitamin D levels were significantly lower (P = 0.04). However, there was no statistically significant change in serum calcium levels between severe and non-severe COVID-19 patients (P = 0.7) despite the high prevalence of hypocalcemia in our cohort (88%, 86/98). There was no statistically significant difference in the blood levels of both vitamin D and calcium between the improved group of patients and the death group (P = 0.5, 0.1 respectively). Conclusion: Vitamin D deficiency is a risk factor for disease progression and severity in COVID-19 patients. Hypocalcemia is not linked to COVID-19 severity despite its high prevalence in these patients. However, to back up these findings, more research with bigger sample size is required .
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 7 (3) , 297-304
Liver function test abnormalities in COVID-19 patients and factors affecting them – a retrospective study
Introduction We aimed to study liver function test abnormalities in our COVID-19 patients and factors affecting them and to evaluate whether liver function test abnormalities are related to the severity of COVID-19. Material and methods Our retrospective study included 118 patients who were...
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 7 (3) , 297-304
Open AccessLiver function test abnormalities in COVID-19 patients and factors affecting them – a retrospective study
Introduction We aimed to study liver function test abnormalities in our COVID-19 patients and factors affecting them and to evaluate whether liver function test abnormalities are related to the severity of COVID-19. Material and methods Our retrospective study included 118 patients who were...
- Open Access
- 10 June 2020
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
- p. 15-19
Liver Involvement in COVID-19 infected patients
Coronavirus outbreak in December 2019 was reported in the city of Wuhan, China firstly named 2019 novel coronavirus (2019-nCoV). Later on, the World Health Organization (WHO) declared another name for this disease which is Corona Virus Disease (COVID-19). On the eleventh of March, 2020, WHO considered the disease as a pandemic. Person-to-person transmission has been reported either through droplet transmission or direct contact. The affected individuals complain from mild symptoms to severe acute respiratory syndrome (ARDS). With the increasing number of COVID-19 infected patients, several studies reported that the liver is the most frequently affected organ after lung damage. Elevation of transaminases was frequently reported in patients with severe disease and patients admitted to ICU. The mechanism of hepatic injury in COVID-19 not completely understood. Multiple factors have been accused including direct invasion of the hepatocyte by SARS-CoV-2, high level of inflammatory mediators, drug-induced hepatic injury, and or concomitant chronic liver diseases. So, evaluation of the mechanism of hepatic injuries in COVID-19 infection is needed.
- 10 June 2020
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
- p. 15-19
Open AccessLiver Involvement in COVID-19 infected patients
Coronavirus outbreak in December 2019 was reported in the city of Wuhan, China firstly named 2019 novel coronavirus (2019-nCoV). Later on, the World Health Organization (WHO) declared another name for this disease which is Corona Virus Disease (COVID-19). On the eleventh of March, 2020, WHO considered the disease as a pandemic. Person-to-person transmission has been reported either through droplet transmission or direct contact. The affected individuals complain from mild symptoms to severe acute respiratory syndrome (ARDS). With the increasing number of COVID-19 infected patients, several studies reported that the liver is the most frequently affected organ after lung damage. Elevation of transaminases was frequently reported in patients with severe disease and patients admitted to ICU. The mechanism of hepatic injury in COVID-19 not completely understood. Multiple factors have been accused including direct invasion of the hepatocyte by SARS-CoV-2, high level of inflammatory mediators, drug-induced hepatic injury, and or concomitant chronic liver diseases. So, evaluation of the mechanism of hepatic injuries in COVID-19 infection is needed.
- 16 December 2019
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
Hepatitis C Virus Treatment Update
Hepatitis C virus (HCV) infection is a worldwide public health problem where anti-HCV prevalence had an estimated 2.8% increase over the last decade, corresponding to more than 185 million infections (3% of the world’s population). Treatment of chronic HCV was based on interferon-α for more than 20 years. Over the last years, the treatment of chronic hepatitis C was evolving rapidly with the development of Interferon-free regimens with direct-acting antiviral agents (DAAs). These regimens induce higher rates of sustained virological response (SVR) and show a favorable safety profile compared with IFN-based treatments. The objective of chronic hepatitis C treatment is to achieve SVR which is defined as the absence of viral replication at 12 or 24 weeks after treatment completion. SVR reduces morbidity and mortality and is equivalent in most cases to cure the HCV infection. When considering a patient for HCV therapy, three important pieces of information are needed to guide the treatment plan for all patients: genotype, prior treatment history, and stage of liver disease
- 16 December 2019
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
Hepatitis C Virus Treatment Update
Hepatitis C virus (HCV) infection is a worldwide public health problem where anti-HCV prevalence had an estimated 2.8% increase over the last decade, corresponding to more than 185 million infections (3% of the world’s population). Treatment of chronic HCV was based on interferon-α for more than 20 years. Over the last years, the treatment of chronic hepatitis C was evolving rapidly with the development of Interferon-free regimens with direct-acting antiviral agents (DAAs). These regimens induce higher rates of sustained virological response (SVR) and show a favorable safety profile compared with IFN-based treatments. The objective of chronic hepatitis C treatment is to achieve SVR which is defined as the absence of viral replication at 12 or 24 weeks after treatment completion. SVR reduces morbidity and mortality and is equivalent in most cases to cure the HCV infection. When considering a patient for HCV therapy, three important pieces of information are needed to guide the treatment plan for all patients: genotype, prior treatment history, and stage of liver disease
- 5 December 2019
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
Efficacy, Safety, and Biochemical response of Sofosbuvir-Based Combinations in Treatment of Chronic Hepatitis C Patients in Sohag Governorate
Background and aims: Worldwide Interferon-free regimens with direct acting antiviral agents (DAAs) are the standard treatment for chronic hepatitis today. Different studies have shown that DAAs have favorable safety profile and high rates of sustained virological response (SVR) compared with IFN-based treatments. Therefore, this study aims to assess the rate SVR in patients treated with sofosbuvir-based regimens in Sohag Governate and to evaluate the adverse events (AEs) and the biochemical response to therapy in the studied patients. Patients and Methods: Our study was a prospective one conducted on 135 patients eligible for treatment with sofosbuvir-based regimens. Patients were categorized into two groups: Group 1 (easy to treat) which was treated with dual therapy (sofosbuvir plus daclatasvir) and group 2 (difficult to treat) which was treated with triple therapy (sofosbuvir plus daclatasvir with ribavirin). The efficacy and safety of the treatments were evaluated. Liver function tests were assessed at baseline, at 4 weeks, at end of treatment (EOT) and at 12-week post-treatment follow-up.Results: SVR12 was nearly equal in patients who received dual and triple therapy (98.5%). The most common reported AEs were headache and fatigue. There was a significant improvement in liver function parameters at SVR12.Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin (RBV) were highly effective and well-tolerated.
- 5 December 2019
- Published by Egyptian Knowledge Bank in Sohag Medical Journal
Efficacy, Safety, and Biochemical response of Sofosbuvir-Based Combinations in Treatment of Chronic Hepatitis C Patients in Sohag Governorate
Background and aims: Worldwide Interferon-free regimens with direct acting antiviral agents (DAAs) are the standard treatment for chronic hepatitis today. Different studies have shown that DAAs have favorable safety profile and high rates of sustained virological response (SVR) compared with IFN-based treatments. Therefore, this study aims to assess the rate SVR in patients treated with sofosbuvir-based regimens in Sohag Governate and to evaluate the adverse events (AEs) and the biochemical response to therapy in the studied patients. Patients and Methods: Our study was a prospective one conducted on 135 patients eligible for treatment with sofosbuvir-based regimens. Patients were categorized into two groups: Group 1 (easy to treat) which was treated with dual therapy (sofosbuvir plus daclatasvir) and group 2 (difficult to treat) which was treated with triple therapy (sofosbuvir plus daclatasvir with ribavirin). The efficacy and safety of the treatments were evaluated. Liver function tests were assessed at baseline, at 4 weeks, at end of treatment (EOT) and at 12-week post-treatment follow-up.Results: SVR12 was nearly equal in patients who received dual and triple therapy (98.5%). The most common reported AEs were headache and fatigue. There was a significant improvement in liver function parameters at SVR12.Conclusion: Sofosbuvir plus daclatasvir with or without ribavirin (RBV) were highly effective and well-tolerated.